RankAlpha logo
Back to Rankings

ARGX

argenx SEC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
+
Peers tracked
11
U.S. public peers
Grade Position
Below peers
vs peer average
ARGX vs peer average
43/100
ARGX vs. peer average (C vs. C)
Grade spread
A 1 · B 5 · C 4 · F 1
Graded peers loaded
Coverage
11 graded
100% of tracked

Peer overview

IMVT is the first available peer comparator.

Immunovant is a more direct FcRn competitor than broad large-cap pharma peers because its pipeline targets MG and CIDP with batoclimab and IMVT-1402; ARGX's premium depends on VYVGART maintaining commercial and dosing advantages as those programs mature.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerIMVTImmunovant
ARGX
argenx SE
IMVT
Immunovant
Grade
C
C
Momentum
81
74
Value
60
41
Sentiment
53
59
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Mixed
Open Side-by-Side ComparisonCompare all

Grade position vs IMVT

ARGX / IMVT
Grade Position
Below peers
ARGX vs. peer average (C vs. C)
43/100
Momentum
81
ARGX
Value
60
ARGX
Sentiment
53
IMVT

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs ARGX
1
IMVT
IMVT
C
60/100
Even
2
UCB
UCB
C
60/100
Even
3
JNJ
JNJ
B
80/100
-1
4
TAK
Takeda Pharmaceutical Co Ltd ADR
C
60/100
Even
5
RVMD
Revolution Medicines Inc Common
F
20/100
+2
IMVT is the first peer returned for this comparison set.